



Clinical trial results:

Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer's type under treatment with increasing dosages of intravenous immunoglobulin (octagam® 10%)

Summary

EudraCT number	2007-007134-19
Trial protocol	DE
Global end of trial date	21 September 2010

Results information

Result version number	v1 (current)
This version publication date	04 January 2017
First version publication date	04 January 2017

Trial information

Trial identification

Sponsor protocol code	GAM10-04
-----------------------	----------

Additional study identifiers

ISRCTN number	ISRCTN64846759
ClinicalTrials.gov id (NCT number)	NCT00812565
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Octapharma AG
Sponsor organisation address	Seidenstrasse 2, Lachen, Switzerland, CH-8853
Public contact	Clinical Research and Development Octapharma Pharmazeutica Produktionsgesellschaft m.b.H, Octapharma Pharmazeutica Produktionsgesellschaft m.b.H, +43 1 61032-0,
Scientific contact	Clinical Research and Development Octapharma Pharmazeutica Produktionsgesellschaft m.b.H, Octapharma Pharmazeutica Produktionsgesellschaft m.b.H, +43 1 61032-0,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 November 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 September 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate the decrease of A β in the CNS and the increase in blood plasma, thereby corroborating the assumed primary mechanism of action of IVIG in AD patients, namely the interference with the pathomechanism for AD ("amyloid cascade hypothesis").

Protection of trial subjects:

This trial was conducted in accordance to the principles of GCP, ensuring that the rights, safety and well-being of patients are protected and in consistency with the Declaration of Helsinki. Inclusion and exclusion criteria were carefully defined in order to protect subjects from contraindications, interactions with other medication and risk factors associated with the investigational medicinal product. Throughout the study safety was assessed, such as occurrence of AEs, safety labs, vital signs and physical/neurological examinations, safety MRI.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 February 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 18
Country: Number of subjects enrolled	United States: 37
Worldwide total number of subjects	55
EEA total number of subjects	18

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	14
From 65 to 84 years	40
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The first patient was enrolled February 2, 2009. The last patient study visit was September 21, 2010. Patients were enrolled in this study from a variety of settings including private practice clinics and hospitals. There were 12 study sites, 5 in Germany and 7 in the United States.

Pre-assignment

Screening details:

Qualified patients meeting all inclusion exclusion criteria and providing informed consent were enrolled into the trial.

Period 1

Period 1 title	Full Analyses Set
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo Every 2 Weeks

Arm description:

Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	0.1 g/kg Octagam 10% Every 2 Weeks
------------------	------------------------------------

Arm description:

Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Experimental
Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	0.25 g/kg Octagam 10% Every 2 Weeks
------------------	-------------------------------------

Arm description:

Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Arm title	0.4 g/kg Octagam 10% Every 2 Weeks
Arm description:	
Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Arm type	Experimental
Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Arm title	Placebo Every 4 Weeks
Arm description:	
Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Arm title	0.2 g/kg Octagam 10% Every 4 Weeks
Arm description:	
Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Arm type	Experimental
Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Arm title	0.5 g/kg Octagam 10% Every 4 Weeks
Arm description:	
Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	
Arm type	Experimental

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 0.5 g/kg Octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Arm title	0.8 g/kg Octagam 10% Every 4 Weeks
------------------	------------------------------------

Arm description:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Arm type	Experimental
Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Number of subjects in period 1	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks
Started	7	6	7
Completed	7	6	7

Number of subjects in period 1	0.4 g/kg Octagam 10% Every 2 Weeks	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks
Started	7	7	6
Completed	7	7	6

Number of subjects in period 1	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks
Started	8	7
Completed	8	7

Period 2

Period 2 title	Completed
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Placebo Every 2 Weeks
------------------	-----------------------

Arm description:

Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
--	---------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	0.1 g/kg Octagam 10% Every 2 Weeks
------------------	------------------------------------

Arm description:

Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	0.25 g/kg Octagam 10% Every 2 Weeks
------------------	-------------------------------------

Arm description:

Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	0.4 g/kg Octagam 10% Every 2 Weeks
------------------	------------------------------------

Arm description:

Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Arm title	Placebo Every 4 Weeks
------------------	-----------------------

Arm description:

Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Placebo
--	---------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Arm title	0.2 g/kg Octagam 10% Every 4 Weeks
------------------	------------------------------------

Arm description:

Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Arm title	0.5 g/kg Octagam 10% Every 4 Weeks
------------------	------------------------------------

Arm description:

Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received 0.5 g/kg Octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Arm title	0.8 g/kg Octagam 10% Every 4 Weeks
------------------	------------------------------------

Arm description:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Octagam 10%, human normal immunoglobulin solution ready for intravenous administration
--	--

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Solution for infusion
----------------------	-----------------------

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Number of subjects in period 2	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks
Started	7	6	7
Completed	5	6	7
Not completed	2	0	0
Consent withdrawn by subject	1	-	-
Adverse Event	-	-	-
Did Not Come To Study Visit	1	-	-

Number of subjects in period 2	0.4 g/kg Octagam 10% Every 2 Weeks	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks
Started	7	7	6
Completed	5	6	6
Not completed	2	1	0
Consent withdrawn by subject	-	1	-
Adverse Event	2	-	-
Did Not Come To Study Visit	-	-	-

Number of subjects in period 2	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks
Started	8	7
Completed	8	6
Not completed	0	1
Consent withdrawn by subject	-	-
Adverse Event	-	1
Did Not Come To Study Visit	-	-

Baseline characteristics

Reporting groups	
Reporting group title	Placebo Every 2 Weeks
Reporting group description: Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.1 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.25 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.4 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	Placebo Every 4 Weeks
Reporting group description: Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.2 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.5 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.8 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	

Reporting group values	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks
Number of subjects	7	6	7
Age categorical Units: Subjects			
From 51-86 years	7	6	7
Age continuous Units: years			
arithmetic mean	72.57	66.83	68.29
standard deviation	± 9.24	± 5.53	± 4.15
Gender categorical Units: Subjects			
Female	4	1	3
Male	3	5	4

Reporting group values	0.4 g/kg Octagam 10% Every 2 Weeks	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks
Number of subjects	7	7	6

Age categorical Units: Subjects			
From 51-86 years	7	7	6
Age continuous Units: years			
arithmetic mean	72.86	71.43	74.83
standard deviation	± 5.01	± 11.76	± 5.46
Gender categorical Units: Subjects			
Female	3	5	2
Male	4	2	4

Reporting group values	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks	Total
Number of subjects	8	7	55
Age categorical Units: Subjects			
From 51-86 years	8	7	55
Age continuous Units: years			
arithmetic mean	65.88	68.43	-
standard deviation	± 10.19	± 8.62	-
Gender categorical Units: Subjects			
Female	3	3	24
Male	5	4	31

End points

End points reporting groups

Reporting group title	Placebo Every 2 Weeks
Reporting group description: Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.1 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.25 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.4 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	Placebo Every 4 Weeks
Reporting group description: Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.2 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.5 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.8 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	Placebo Every 2 Weeks
Reporting group description: Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.1 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.25 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	0.4 g/kg Octagam 10% Every 2 Weeks
Reporting group description: Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).	
Reporting group title	Placebo Every 4 Weeks
Reporting group description: Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.2 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).	
Reporting group title	0.5 g/kg Octagam 10% Every 4 Weeks
Reporting group description: Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).	

Reporting group title	0.8 g/kg Octagam 10% Every 4 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Primary: Change in the Area Under the Curve (AUC) of Plasma A β 1-40 in the 2 or 4 weeks after the last treatment infusion from the trough level prior to the last treatment infusion

End point title	Change in the Area Under the Curve (AUC) of Plasma A β 1-40 in the 2 or 4 weeks after the last treatment infusion from the trough level prior to the last treatment infusion ^[1]
-----------------	---

End point description:

For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining A β 1-40 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma A β forms; Gent, Belgium).

End point type	Primary
----------------	---------

End point timeframe:

Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Results are provided as Change in the Area Under the Curve of Plasma A β 1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion

End point values	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks	0.4 g/kg Octagam 10% Every 2 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	6	7	5
Units: (pg/mL)*days]				
arithmetic mean (standard deviation)	161.2 (\pm 93.9)	-245.67 (\pm 747.58)	-122.5 (\pm 478.31)	-39.1 (\pm 172.72)

End point values	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	8	6
Units: (pg/mL)*days]				
arithmetic mean (standard deviation)	510.92 (\pm 2395.8)	-83.67 (\pm 957.69)	-755.38 (\pm 2232.87)	-262.92 (\pm 671.37)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were monitored throughout the entire study period, starting from the baseline visit until the final study visit.

Adverse event reporting additional description:

Safety set: All randomized participants who received at least 1 infusion of study medication

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.0
--------------------	------

Reporting groups

Reporting group title	Placebo Every 2 Weeks
-----------------------	-----------------------

Reporting group description:

Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Reporting group title	0.1 g/kg Octagam 10% Every 2 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received 0.1 g/kg Octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).

Reporting group title	0.25 g/kg Octagam 10% Every 2 Weeks
-----------------------	-------------------------------------

Reporting group description:

Participants received 0.25 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Reporting group title	0.4 g/kg Octagam 10% Every 2 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received of 0.4 g/kg Octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).

Reporting group title	Placebo Every 4 Weeks
-----------------------	-----------------------

Reporting group description:

Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Reporting group title	0.2 g/kg Octagam 10% Every 4 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).

Reporting group title	0.5 g/kg Octagam 10% Every 4 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Reporting group title	0.8 g/kg Octagam 10% Every 4 Weeks
-----------------------	------------------------------------

Reporting group description:

Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).

Serious adverse events	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Surgical and medical procedures			
Knee arthroplasty			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal laminectomy			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Convulsion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's type			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric antral vascular ectasia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aggression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	0.4 g/kg Octagam 10% Every 2 Weeks	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Knee arthroplasty			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal laminectomy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Convulsion			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's type			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric antral vascular ectasia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aggression			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from	0	0	

adverse events			
Surgical and medical procedures			
Knee arthroplasty			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal laminectomy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Convulsion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastric antral vascular ectasia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aggression			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo Every 2 Weeks	0.1 g/kg Octagam 10% Every 2 Weeks	0.25 g/kg Octagam 10% Every 2 Weeks
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 7 (71.43%)	4 / 6 (66.67%)	5 / 7 (71.43%)
Vascular disorders			
Blood pressure fluctuation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vasoconstriction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1

Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Infusion site extravasation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Submandibular mass			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Respiratory tract congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Blood iron decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood pressure decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
CSF white blood cell count positive			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Anxiety postoperative			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1

Fall			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Periorbital haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Post lumbar puncture syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Post procedural constipation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Procedural headache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Procedural hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	2 / 6 (33.33%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Dizziness			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Essential tremor			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	2
Hypertonia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hyporeflexia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Paraesthesia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Iron deficiency anaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Hearing impaired			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Eye disorders			

Glaucoma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders			
Colitis microscopic subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Colonic polyp subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Gastrointestinal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Hiatus hernia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Vomiting subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Actinic keratosis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Ecchymosis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Hyperkeratosis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Pruritus			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 2
Rotator cuff syndrome subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Tooth abscess subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0

Non-serious adverse events	0.4 g/kg Octagam 10% Every 2 Weeks	Placebo Every 4 Weeks	0.2 g/kg Octagam 10% Every 4 Weeks
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 7 (42.86%)	3 / 7 (42.86%)	4 / 7 (57.14%)
Vascular disorders			
Blood pressure fluctuation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vasoconstriction			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infusion site extravasation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Submandibular mass			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Respiratory tract congestion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Depression subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Blood magnesium decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0

Blood potassium decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Blood pressure decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
CSF white blood cell count positive subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications			
Anxiety postoperative subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Periorbital haematoma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Post lumbar puncture syndrome subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Post procedural constipation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Post procedural haemorrhage subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Procedural headache			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Procedural hypertension subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Nervous system disorders Cerebral haemorrhage subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Essential tremor subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Hypertonia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hyporeflexia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Paraesthesia			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Ear and labyrinth disorders Hearing impaired subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Eye disorders Glaucoma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders Colitis microscopic subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Colonic polyp subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hiatus hernia			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Actinic keratosis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Ecchymosis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hyperkeratosis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders			
Haematuria subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Muscle spasms subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rotator cuff syndrome subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Infections and infestations			

Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	0.5 g/kg Octagam 10% Every 4 Weeks	0.8 g/kg Octagam 10% Every 4 Weeks	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 8 (50.00%)	4 / 7 (57.14%)	
Vascular disorders			
Blood pressure fluctuation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Hypertension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Hypotension			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Vasoconstriction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			

Chills			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Influenza like illness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Infusion site extravasation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Submandibular mass			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Respiratory tract congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Confusional state			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	0 / 8 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Insomnia			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Blood magnesium decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Blood potassium decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Blood pressure decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
CSF white blood cell count positive subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Injury, poisoning and procedural complications			
Anxiety postoperative subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	

Contusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Fall			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Periorbital haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Post lumbar puncture syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Post procedural constipation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Procedural headache			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Procedural hypertension			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Procedural pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	1 / 8 (12.50%)	1 / 7 (14.29%)	
occurrences (all)	1	1	
Dizziness			

subjects affected / exposed	0 / 8 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Essential tremor			
subjects affected / exposed	0 / 8 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Headache			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Hypertonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Hypoaesthesia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Hyporeflexia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Tremor			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Iron deficiency anaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 7 (0.00%)	
occurrences (all)	0	0	
Lymphadenopathy			
subjects affected / exposed	1 / 8 (12.50%)	0 / 7 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Hearing impaired			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Eye disorders Glaucoma subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Gastrointestinal disorders Colitis microscopic subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Colonic polyp subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Dyspepsia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Gastrointestinal pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Hiatus hernia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Vomiting subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Skin and subcutaneous tissue disorders Actinic keratosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Ecchymosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Hyperkeratosis			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Pruritus subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Muscle spasms subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Rotator cuff syndrome subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Tooth abscess subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1	
Tooth infection subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0	
Urinary tract infection			

subjects affected / exposed	0 / 8 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 June 2009	Amendment 1 (global, dated 10 June 2009): The changes were a result of issues encountered during the initial conduct of the trial that identified protocol requirements that were impractical and/or unnecessary for the study conduct. Other changes were administrative corrections or clarification of existing language. The specified changes referred to numbers of sites per country, time windows, sample collection and laboratory procedures and to the procedure of obtaining informed consent.
07 October 2009	Some mistakes/inconsistencies made in protocol version 2.3 were corrected. The specified changes referred to the numbers of sites per country and time windows.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Small numbers of patients per treatment group (between 5 and 8) and variable total A β levels over time.
--

Notes: